Press Release

March 2, 2026

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

VERAXA's shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp.

September 30, 2025

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

The partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases.

July 17, 2025

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets and vision of bringing the next generation of safe and highly effective cancer therapies to patients.